High-throughput ex vivo tissue assay for stress mitigation prediction
This innovative ex vivo tissue assay uses human skin explants with innate immune cells to predict and analyze stress-induced inflammation effects on hair follicles. Ideal for understanding stress impacts and developing protective or restorative interventions.
Overview
This high-throughput ex vivo tissue assay offers a sophisticated platform for predicting and analyzing the effects of stress-induced inflammation on hair follicles. By simulating stress conditions using hormones like cortisol and adrenaline, the assay provides valuable insights into the biological impacts on hair growth cycles, follicle structure, and cell viability. It is designed to help researchers and companies understand how stress-related changes in immune responses, such as elevated pro-inflammatory cytokines, affect hair follicle health.
Technical specifications
Key features:
- Utilizes human skin tissue explants incorporating both innate immune cells and peripheral blood immune cells from the same donor.
- Simulates stress conditions by applying stress hormones directly to skin explants.
- Measures various response parameters, including histological damage, cytokine levels, immune cell infiltration, and specific markers of stress and inflammation through techniques like immunofluorescence and RNA sequencing.
- Tailors readouts to client needs, offering flexibility in research applications.
Technology readiness level
This assay has achieved a Technology Readiness Level (TRL) of 6, indicating it is a system/subsystem model or prototype demonstration in a relevant environment. The technology has been applied in projects like the study of Hidradenitis suppurativa, focusing on hair follicle inflammation, demonstrating its practical application potential.
About Alcyomics ltd
Alcyomics Ltd. is a clinical research organization (CRO) based in Newcastle, UK, that provides non-animal human in vitro assays for safety and efficacy testing. The company specializes in immunotoxicology and drug development, utilizing its patented Skimune® platform, a human skin explant assay. By using human tissue-based models, the technology accurately predicts human immune responses to various compounds, including small molecules, biologics, monoclonal antibodies, and advanced therapies, serving as a reliable alternative to traditional animal testing.
The services provided by Alcyomics help pharmaceutical, biotechnology, and cosmetics clients de-risk their product portfolios, improve clinical trial outcomes, and accelerate time-to-market. Their assays are highly customizable and have been used in various applications ranging from early-stage drug discovery and safety assessments for first-in-human studies to efficacy testing for immunomodulators and cellular therapies. The company operates under Good Laboratory Practice and ISO9001 standards, with its research extensively published in peer-reviewed journals to support regulatory submissions and clinical trial applications.
delivered to your inbox.